富马酸替诺福韦二吡呋酯在初治低病毒载量慢性乙型病毒性肝炎患者中的治疗效果观察  

Effect observation of tenofovir disoproxil fumarate in initially treatment of chronic viral hepatitis B patients with with low viral load

作　　者：赵林 杨长河 耿元元 ZHAO Lin;YANG Chang-he;GENG Yuan-yuan(Infectious Diseases Department,PLA 941st Hospital,Xining 810007,China)

机构地区：[1]解放军第九四一医院感染科,810007

出　　处：《中国现代药物应用》2025年第6期83-86,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探究对初治低病毒载量慢性乙型病毒性肝炎(CHB)运用富马酸替诺福韦二吡呋酯治疗的效果。方法选取110例初治低病毒载量CHB患者为受试者,以随机抽签法分为对照组(55例)及观察组(55例)。对照组行恩替卡韦胶囊治疗,观察组行富马酸替诺福韦二吡呋酯片治疗。比较两组肝功能指标[天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、总胆红素(TBiL)、白蛋白(ALB)],乙型肝炎病毒表面抗原(HBsAg)、乙型肝炎病毒脱氧核糖核酸(HBV-DNA)载量与HBVDNA阴转率,不良反应发生情况,临床效果。结果治疗后,观察组AST(21.65±4.23)U/L、ALT(22.13±5.04)U/L、TBiL(30.19±8.13)μmol/L低于对照组的(28.70±3.88)U/L、(37.74±4.48)U/L、(39.56±7.34)μmol/L,ALB(49.66±0.71)g/L高于对照组的(33.76±1.82)g/L,差异具备统计学价值(P<0.05)。治疗后,观察组HBsAg(1.28±0.17)lgIU/ml、HBV-DNA载量(1.55±0.11)lgcopies/ml比对照组的(2.34±0.21)lgIU/ml、(2.09±0.17)lgcopies/ml更低,差异具备统计学价值(P<0.05)。与对照组的49.09%比较,观察组HBVDNA阴转率70.91%更高,差异具备统计学价值(P<0.05)。两组不良反应发生率比较,差异不明显(χ^(2)=0.909,P=0.340>0.05)。观察组总有效率为94.55%(52/55),对照组总有效率为80.00%(44/55)。观察组总有效率高于对照组,差异具备统计学价值(P<0.05)。结论对初治低病毒载量CHB患者行富马酸替诺福韦二吡呋酯治疗的效果突出,可促进患者肝功能恢复,减轻患者炎症反应,且安全性较高。Objective To explore the effect of tenofovir disoproxil fumarate in initially treatment of chronic viral hepatitis B(CHB)patients with with low viral load.Methods A total of 110 CHB patients with low viral load were selected and divided into control group(55 cases)and observation group(55 cases)by random lottery method.The control group was treated with entecavir capsule,and the observation group was treated with tenofovir disoproxil fumarate tablet.Both groups were compared in terms of liver function indexes[aspartate aminotransferase(AST),alanine aminotransferase(ALT),total bilirubin(TBiL),albumin(ALB)],hepatitis B virus surface antigen(HBsAg),hepatitis B virus deoxyribonucleic acid(HBV-DNA)load and HBV-DNA negative conversion rate,occurrence of adverse reactions,and clinical effects.Results After treatment,the observation group had AST of(21.65±4.23)U/L,ALT of(22.13±5.04)U/L and TBiL of(30.19±8.13)μmol/L,which were lower than(28.70±3.88)U/L,(37.74±4.48)U/L and(39.56±7.34)μmol/L in the control group;the observation group had a higher ALB of(49.66±0.71)g/L than(33.76±1.82)g/L in the control group;the difference was statistically valuable(P<0.05).After treatment,the observation group had HBsAg of(1.28±0.17)lgIU/ml and HBV-DNA load of(1.55±0.11)lgcopies/ml,which were lower than(2.34±0.21)lgIU/ml and(2.09±0.17)lgcopies/ml in the control group,and the difference was statistically valuable(P<0.05).The HBV-DNA negative conversion rate of 70.91%in the observation group was higher than 49.09%in the control group,and the difference was statistically valuable(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(χ^(2)=0.909,P=0.340>0.05).The total effective rate was 94.55%(52/55)in the observation group and 80.00%(44/55)in the control group;the total effective rate of the observation group was higher than that of the control group,and the difference was statistically valuable(P<0.05).Conclusion Tenofovir disoproxil fumarate is effective in initial treatment

关 键 词：初治 低病毒载量 慢性乙型病毒性肝炎 富马酸替诺福韦二吡呋酯 

分 类 号：R51[医药卫生—内科学]